1. Genetic activation of Nrf2 reduces cutaneous symptoms in a murine model of Netherton syndrome.
- Author
-
Muzumdar S, Koch M, Hiebert H, Bapst A, Gravina A, Bloch W, Beer HD, Werner S, and Schäfer M
- Subjects
- Animals, Cell Adhesion, Cell Differentiation, Chemokines metabolism, Disease Models, Animal, Epidermis pathology, Humans, Inflammation pathology, Inflammation Mediators metabolism, Integrases metabolism, Keratinocytes pathology, Mice, Inbred C57BL, Mice, Knockout, NAD(P)H Dehydrogenase (Quinone) metabolism, NF-E2-Related Factor 2 metabolism, Secretory Leukocyte Peptidase Inhibitor metabolism, Serine Peptidase Inhibitor Kazal-Type 5 deficiency, Serine Peptidase Inhibitor Kazal-Type 5 genetics, NF-E2-Related Factor 2 genetics, Netherton Syndrome genetics, Netherton Syndrome pathology, Skin pathology
- Abstract
Netherton syndrome is a monogenic autosomal recessive disorder primarily characterized by the detachment of the uppermost layer of the epidermis, the stratum corneum It results from mutations in the SPINK5 gene, which codes for a kallikrein inhibitor. Uncontrolled kallikrein activity leads to premature desquamation, resulting in a severe epidermal barrier defect and subsequent life-threatening systemic infections and chronic cutaneous inflammation. Here, we show that genetic activation of the transcription factor nuclear factor (erythroid-derived 2)-like 2 (Nfe2l2/Nrf2) in keratinocytes of Spink5 knockout mice, a model for Netherton syndrome, significantly alleviates their cutaneous phenotype. Nrf2 activation promoted attachment of the stratum corneum and concomitant epidermal barrier function, and reduced the expression of pro-inflammatory cytokines such as tumor necrosis factor α and thymic stromal lymphopoietin. Mechanistically, we show that Nrf2 activation induces overexpression of secretory leukocyte protease inhibitor (Slpi), a known inhibitor of kallikrein 7 and elastase 2, in mouse and human keratinocytes in vivo and in vitro , respectively. In the Spink5-deficient epidermis, the upregulation of Slpi is likely to promote stabilization of corneodesmosomes, thereby preventing premature desquamation. Our results suggest pharmacological NRF2 activation as a promising treatment modality for Netherton syndrome patients.This article has an associated First Person interview with the first author of the paper., Competing Interests: Competing interestsThe authors declare no competing or financial interests., (© 2020. Published by The Company of Biologists Ltd.)
- Published
- 2020
- Full Text
- View/download PDF